Consequently, treatment guidelines for IBD and rheumatic diseases have been adapted accordingly and include TNF-α inhibitors in their recommendations, making TNF-α inhibitors an important option in the therapeutic landscape. This evidence concerns the gene TNF and rheumatic disorder.